Novel biomarkers for risk stratification of acute coronary syndromes.
DOI:
https://doi.org/10.7439/ijbr.v6i8.2346Abstract
Acute coronary syndromes are one of the most important causes of death world-wide. The clinical diagnosis, though is correct in majority of the cases, it is not cent percent, which is not acceptable when the life of the patient is at stake. Various biomarkers have been tested and found useful in diagnosing, ruling out, prognostication and risk stratification of the acute coronary syndromes. These biomarkers have the potential to change the management of the acute coronary syndromes, making the management of acute coronary syndromes more precise and more accurate.Downloads
References
Morgenthaler NG, Struck J, Jochberger S, D
Roger Acher; Jacqueline Chauvet; Yves Rouille "Dynamic processing of neuropeptides: sequential conformation shaping of neurophypophysical preprohomones during intraneural secretory transport". Journal of Molecular Neuroscience 18 (3): 223
Nils Morgenthaler; Joachim Struck; Stefan Jochberger; Martin D
Steve Lin, Hiroyuki Yokoyama, Valeria E. Rac, Steven C. Brooks,Novel biomarkers in diagnosing cardiac ischemia in the emergency department: A systematic review: June 2012, 83.684-91.
Alehagen U, Dahlstrom U, Rehfeld JF, Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure..JAMA 2011, 305(20):2088-2095.
Casas JP, Shah T,Hingorani AD, Danesh J, Pepys MB. CRP and and coronary heart disease:a critical review.
Devaraj S, Singh U, Jialal I. Human C reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009; 20(3): 182
Williamson MA,Snyder LM, Wallach JB. Wallach
Tillett WS, Francis T. Serological reactions in pneumonia with a non protein somatic fraction of pneumococcus. J Exp Med. 1930; 52(4):561-71.
CAA39671.1 G. C- reactive protein
Michelle O
Jonathan Rosman, MD, Gita Kavala: The role of heart-type fatty acid-binding protein in the diagnosis of acute coronary syndrome. Int J Angiol. 2009; 18(2): 79
Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ (Oct 1992). "Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man". Molecular and Cellular Biochemistry 116(1-2): 155
Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp JH, van der Vusse GJ, Reneman RS (Jul 1988). "Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox". Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp JH, van der Vusse GJ, Reneman RS. Biochim Biophys Acta 1988; 961(1):148-52.
McMahon G, Lamont J, Curtin E, McConnell RI, Crockard M, Kurth MJ et al. (2011). "Diagnostic accuracy of H-FABP for the early diagnosis of acute myocardial infarction". American Journal of Emergency Medicine 2012; 30(2): 267
Kaczy
Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O et al. (Mar 2007). "Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic eart failure patients". Journal of Cardiac Failure 13 (2):
Manas K. Sinha, David C. Gaze, John R. Tippins, Paul O. Collinson , Juan Carlos Kaski .Ischemia Modified Albumin Is a Sensitive Marker of Myocardial Ischemia After Percutaneous Coronary Intervention Ischemia: Circulation. 2003; 107: 2403-2405.
Nagesh C Ambuj R. Role of biomarkers in risk stratification of acute coronary syndrome: Indian J Med Res 2010; 132: 627-633.
David C: Ischemia Modified Albumin: A Novel Biomarker for the Detection of Cardiac Ischemia. Drug Metab. Pharmacokinet. 24 (4): 333
Sanchez C, Mosquera B, Sinha A, Collinson M, Gaze D. Ischemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain: Heart Vessels 23, 174-180.
Nader El-Shahhat, Mahmoud M. Ramadan, Nader El-Malkey, Ashraf A. Omar, , Ibrahim A. Abd El-Aal, Asmaa Eneen. Soluble CD40 ligand, interleukin (IL)-6, and hemostatic parameters in metabolic syndrome patients with and without overt ischemic heart disease. The Egyptian Heart Journal 2011); 6; 131
Mehmet Kayrak
Tanja K. Rudolph, Neele Schaper Anna Klinke, Cagri Demir Britta Goldmann, Denise Lau et al. Liberation of vessel-adherent myeloperoxidase reflects plaque burden in patients with stable coronary artery disease. Atherosclerosis 2013; 231(2):354
Mocatta T J, Pilbrow A P, Vicky A. Cameron V A, Senthilmohan R, Chris M. Frampton C M, Richards A M, Winterbourn C C. Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction. J Am Coll Cardiol 2007; 49:1993
Barbara J. Jefferis B J, Whincup P, Welsh P, Wannamethee G, Rumley A, Lennon L. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 2010; 208(2): 557
Heeschen C, Dimmeler S, Hamm CW, et al: Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: Comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 45:229, 2005.
Antoni Bayes
Cheryl A Conover et al
Lenderink T, Heeschen C, Fichtlscherer S, et al: Elevated placental growth factor levels areassociated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am CollCardiol 47:307, 2006.
Scirica BM, Sabatine MS, Jarolim P, et al: Assessment of multiple cardiac biomarkers innon
Riezebos RK, Laarman GJ, Tijssen JG, Verheugt FW. The value of Nterminal proBtypenatriuretic peptide for early identification of myocardial infarction in patients with high risk nonSTelevation acute coronary syndromes. Clin Chem Lab Med. 2011?49:1359
Ordonez Llanos J, Collinson PO, Christenson RH. Aminoterminal pro B type natriuretic peptide: analytic considerations. Am J Cardiol 2008?101:9-15.
Jernberg T, James S, Lindahl B, Johnston N, Stridsberg M, Venge P, et al. Natriuretic peptides in unstable coronary artery disease. Eur Heart J. 2004?25:1486
Truong QA, Bayley J, Hoffmann U, Bamberg F, Schlett CL, Nagurney JT, et al. Multimarker strategy of natriuretic peptide with either conventional or highsensitivity troponinT for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the "Rule Out Myocardial Infarction using Computer Assisted Tomography" (ROMICAT) trial. Am Heart J. 2012?163:972
Mathewkutty S, Sethi SS, Aneja A, Shah K, Iyengar RL, Hermann L, et al. Biomarkers after risk stratification in acute chest pain (from the BRIC Study) Am J Cardiol. 2013?111:493
McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of leftventricular systolic dysfunction. Lancet 1998?351:9
Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive aminoterminal Probrain natriuretic peptide (NTPROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997?47:287
OrdonezLlanos J, Collinson PO, Christenson RH. Aminoterminal proBtype natriuretic peptide: analytic considerations. Am J Cardiol. 2008?101:9
Bruder O, Jensen C, Jochims M, Farazandeh M, Barkhausen J, Schlosser T, Sabin GV, Hunold P. Relation of Btype natriuretic peptide (BNP) and infarct size as assessed by contrast enhanced MRI. Int J Cardiol. 2009?144:53
Truong QA, Bayley J, Hoffmann U, Bamberg F, Schlett CL, Nagurney JT, et al. Multimarker strategy of natriuretic peptide with either conventional or high sensitivity troponinT for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the "Rule Out Myocardial Infarction using Computer Assisted Tomography" (ROMICAT) trial. Am Heart J. 2012?163:972
Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R., Jr National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem. 1999?45:1104
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.